ReviewJournal of personalized medicine2023
The Role of Nodes and Nodal Assessment in Diagnosis, Treatment and Prediction in ER+, Node-Positive Breast Cancer.
Review in Journal of personalized medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07214532 (SIgnatera-Guided Initiation of Adjuvant CDK4/6 Inhibitor in Intermediate Risk HR+ HER2- Breast Cancer), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
SIgnatera-Guided Initiation of Adjuvant CDK4/6 Inhibitor in Intermediate Risk HR+ HER2- Breast Cancer
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ectopic breast cancer in vulva and other non-axillary sites: a systematic review.World journal of surgical oncology · 2026Pooled it
- Lymphovascular Invasion in SOUND-Eligible Breast Cancer: Implications for Occult Axillary Nodal Metastasis.Annals of surgical oncology · 2026Article
- Abemaciclib in HR+, HER2- Breast Cancer: A Narrative Review of the Clinical Evidence.Oncology and therapy · 2026Review
- Reevaluating sentinel lymph node biopsy in older adults with T1 HR+/HER2- breast cancer: a SEER competing risk and nomogram study.Breast cancer (Tokyo, Japan) · 2026Article
- IRIS: Interpretable Risk Clustering Intelligence for Survival Analysis.Proceedings : ... IEEE International Conference on Big Data. IEEE International Conference on Big Data · 2025Article
- Cytoplasmic and nuclear programmed death ligand 1 expression in peritumoral stromal cells in breast cancer: Prognostic and predictive value.World journal of experimental medicine · 2025Article
- Reducing Postoperative Complications in High-Risk Breast Surgery Patients: A Preliminary Study on the Efficacy of NPWT Dressing.Journal of personalized medicine · 2025Article
- Prognostic prediction for HER2-low breast cancer patients using a novel machine learning model.BMC cancer · 2024Article
- Are All Prognostic Stage IB Breast Cancers Equivalent?Cancers · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The majority of breast cancers are oestrogen receptor-positive (ER+). In ER+ cancers, oestrogen acts as a disease driver, so these tumours are likely to be susceptible to endocrine therapy (ET). ET works by blocking the hormone's synthesis or effect. A significant number of patients diagnosed with breast cancer will have the spread of tumour cells into regional lymph nodes either at the time of diagnosis, or as a recurrence some years later. Patients with node-positive disease have a poorer prognosis and can respond less well to ET. The nodal metastases may be genomically similar or, as is becoming more evident, may differ from the primary tumour. However, nodal metastatic disease is often not assessed, and treatment decisions are almost always based on biomarkers evaluated in the primary tumour. This review will summarise the evidence in the field on ER+, node-positive breast cancer, including diagnosis, treatment, prognosis and predictive tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.